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The impact of currently recommended antihypertensive 
therapy on depression and other psychometric parameters: 
preliminary communication
Aims: Current evidence on the psychological effects of antihypertensive medications is contro-
versial. The aim of this study was to evaluate the effect of current antihypertensive medication 
on different psychometric parameters and on serum brain-derived neurotrophic factor (BDNF) 
level. Methods: Psychometric, haemodynamic, arterial stiffness and laboratory parameters 
were evaluated before and 3 months after the initiation of antihypertensive medication in 
untreated hypertensive patients (HT, n=31), and once in healthy controls (CONT, n=22). Sub-
jects completed the following psychometric tests: Beck Depression Inventory (BDI), Hamilton 
Anxiety Scale (HAM-A), Symptom Checklist 90 Revised (SCL-90), Temperament Evaluation of 
Memphis, Pisa, Paris, and San Diego Autoquestionnaire, Big Five Inventory, Pain Vigilance 
and Awareness Questionnaire and Berkeley Expressivity Questionnaire. Amlodipine and/or 
perindopril compounds were preferred medications. Serum BDNF was measured with ELISA. 
Results: Brachial systolic blood pressure, as well as pulse wave velocity were significantly im-
proved in the HT group over the 3-month follow-up (153.3±15.9 mmHg vs. 129.5±10.0 mmHg 
and 8.2±1.4 m/s vs 7.5±1.6 m/s, respectively). Similarly, we found improvements in BDI (0.73 
points) and in several Scl-90 subscales. Serum BDNF was not different between CONT and HT 
and did not change for therapy. Conclusions: Our results indicate that initiation of currently 
recommended antihypertensive medications in newly diagnosed patients may have a signifi-
cant impact on psychological well-being of patients and could influence quality of life as well.
(Neuropsychopharmacol Hung 2017; 19(1): 11–22)
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INTRODUCTION
A causal relationship between elevated blood pres-
sure and cardiovascular morbidity/mortality has been 
clearly demonstrated (Lewington et al., 2002). If life-
style modifications by themselves are insufficient to 
treat hypertension, pharmacological interventions 
are required to control blood pressure and avoid late 
cardiovascular complications. This decision is a com-
plex procedure, where  severity of hypertension, age 
of the patient, presence of comorbidities, total car-
diovascular risk, and additional features of different 
drug classes must also be taken into consideration 
(Mancia et al., 2013). 
Antihypertensive medications from different 
pharmacological classes may cause different side 
effects. In contrast, different agents can also have 
unexpected beneficial effects. For example losartan 
may be beneficial in gout patients (Wurzner et al., 
2001) or nebivolol may improve erectile dysfunction 
(Fongemie and Felix-Getzik, 2015). While impact of 
antihypertensive agents on psychological symptoms 
has also been studied, results are controversial. Case 
reports demonstrated depressive effects of the beta-
blocker propranolol and timolol (McNeil et al., 1982; 
Nolan, 1982). Furthermore, more frequent use of 
antidepressants was observed in patients taking beta-
blockers (Avorn et al., 1986).  A case-control study 
of incident depression cases and population-based 
controls, however, found a null-effect after adjusting 
for potential confounders including co-morbidities 
(Bright and Everitt, 1992). Similarly, the ACE-inhib-
itor enalapril was found to have a depressive effect 
in a case report (Patterson, 1989), however, another 
small-scale study suggested an antidepressive impact 
of enalapril (Braszko et al., 2003). Calcium chan-
nel blockers have been suggested to be associated 
with increased incidence of mood disorders (Hallas, 
1996), but others could not confirm these findings 
(Patten et al., 1995; Dunn et al., 1999). Most of the 
above-mentioned studies were case reports or were 
based on prescription databases allowing for po-
tential bias and confounding. Furthermore, they 
investigated older agents that are not state-of-the-art 
any more. Surprisingly, no data are available about 
the psychosomatic impact of currently preferred 
medications, such as perindopril or amlodipine in 
incident hypertensive patients who are free from 
mood disorders.
Different personality traits or dimensions can also 
influence cardiovascular diseases or risk factors. Trait 
anger was found to be associated with arterial stiffness 
in men (Williams et al., 2006), dominant  cyclothymic 
affective temperament showed correlation with chro-
nic hypertension and with acute coronary events in 
hypertensive patients (Eory et al., 2014b; Eory et al., 
2014a) and cyclothymic temperament score is an in-
dependent determinant of brachial systolic blood 
pressure in chronic hypertension (Laszlo et al., 2016). 
However, no data are available about the stability of 
different dimensions of personality around the initia-
tion of antihypertensive medications. 
Brain-derived neurotrophic factor (BDNF), a 
member of the neurotrophic factor family, plays an 
important role in the regulation of neuronal growth, 
maintenance and survival (Mattson et al., 2004). It's 
involvement in psychiatric disorders is fundamen-
tal and was confirmed by a meta-analysis, as in ma-
jor depressive disorder the decreased serum BDNF 
(seBDNF) level was elevated following a course of 
antidepressant treatment (Sen et al., 2008). It is hy-
pothesized to play a protective role in cardiovascular 
pathophysiology as its higher serum level was found 
to be associated with decreased risk of cardiovascular 
disease and mortality (Kaess et al., 2015). Recently, 
we found elevated seBDNF in chronic hypertension 
(Nemcsik et al., 2016), but its level in drug-free hyper-
tensive patients and its changes for antihypertensive 
therapy has never been studied yet.
The aim of our study was to evaluate the effect of 
modern antihypertensive medications, based mostly 
on perindopril and/or amlodipine on depression, anx-
iety, psychiatric symptoms, affective temperaments 
and different other dimensions of personality and 
seBDNF level. We hypothesized a positive impact 
of these modern medications on depression, anxiety, 
the intensity of psychiatric symptoms in different 
psychopathological dimensions and seBDNF, and the 
stability of affective temperaments and other dimen-
sions of personality. 
METHODS
Patients
This was a cross-sectional and prospective study in 
two urban primary care practices, between August 
2013 and February 2016. In the cross-sectional part 
Caucasian patients with medically untreated essential 
hypertension, grade 1 or 2 (HT) and healthy controls 
(CONT) were included.  Among HT, grade I hyper-
tensive patients who were already in care and trained 
for lifestyle modifications previously and newly rec-
ognized hypertensive patients were also involved. 
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In the HT group patients with atrial fibrillation, treat-
ed depression, anxiety or with dementia potentially 
interfering with the completion of questionnaires 
were excluded. In case of CONT denial of consent 
was the only exclusion criterion. During the screening 
visit, when the patient was evaluated for hyperten-
sion signed informed consent was obtained. Then 
questionnaires were given to the patients, home blood 
pressure monitoring (HBPM) or ambulatory blood 
pressure monitoring (ABPM) were initiated and an 
appointment within a week for arterial stiffness meas-
urement and blood sampling was scheduled. Based 
on HBPM, or ABPM results subjects with white coat 
hypertension were excluded. If the effect of lifestyle 
modification was unable to control blood pressure 
values or the patient reported hypertension-related 
symptoms or either risk factors or absolute cardiovas-
cular risk required treatment, antihypertensive drug 
therapy was initiated based on the current guideline 
(Mancia et al., 2013). 
The choice of the antihypertensive agent was per-
sonalized taking into account the age, sex, comor-
bidities and grade of hypertension, and was based 
on the recent European guideline as well (Mancia 
et al., 2013). Amlodipine from the calcium channel 
blocker group, perindopril from the ACE-inhibitor 
group and indapamide from the diuretic group were 
used as first line agents. When indicated, bisoprolol, 
carvedilol, nebivolol or long-lasting metoprolol were 
the preferred beta-blockers. In subjects with gout the 
uricosuric angiotensin receptor blocker (ARB) losar-
tan was initiated, if an ARB was considered. When 
more than one agent was necessary we preferentially 
initiated the single-pill combination of perindopril 
and amlodipine. Within 10 days after the initiation 
of antihypertensive therapy, patients had a follow-up 
visit and therapy was modified if necessary.
All 31 hypertensive patients took part in the pro-
spective part of the study, when all baseline measure-
ments were repeated 3 months after the initiation of 
antihypertensive medication. No untreated hyper-
tensive control group was formed, as we thought that 
it would be unethical to withhold antihypertensive 
treatment in a population with symptomatic or more 
severe hypertension. Routine laboratory, psychomet-
ric and arterial stiffness parameters were evaluated at 
baseline for hypertensive and control patients. The 
hypertensive group also had repeat measurements 
after 3 months of therapy.
The study was approved by the Scientific and 
Research Ethics Committee of the Medical Research 
Council, the Hungarian Ministry of Health (ETT 
TUKEB 842/PI/2011) and was carried out in accord-
ance with the tenets of the Declaration of Helsinki.
Evaluation of psychometric parameters
The Beck Depression Inventory (BDI) is a 21-question 
multiple-choice self-report questionnaire and is one 
of the most widely used instruments for assessing 
depression severity. Participants are asked to make 
ratings on a four-point scale, where a higher score 
correlates with more severe depression (Beck et al., 
1961). 
The Hamilton Anxiety Scale (HAM-A), evaluated 
by the examiner was used to study the severity of 
anxiety. The scale consists of 14 items, each item is 
scored on a scale of 0 (not present) to 4 (severe anxi-
ety) (Hamilton, 1959). 
The Symptom Checklist 90 Revised (SCL-90), 
a self-rated test consisting of 90 multiple-choice items 
ranging 0–4 (Delogatis, 1994) was used to identify 
the presence and quantify the intensity of psychiatric 
symptoms distributed among 9 psychopathological 
dimensions: 1) somatization; 2) obsessiveness–com-
pulsiveness; 3) interpersonal sensitivity; 4) depres-
sion; 5) anxiety; 6) hostility; 7) phobic anxiety; 8) 
paranoid ideation; 9) psychoticism. The instrument 
has three global indices of distresses as well: the 
global severity index (GSI), the positive symptom 
distress index (PSDI) and the positive symptom total 
(PST). 
The Temperament Evaluation of Memphis, Pisa, 
Paris and San Diego Autoquestionnaire (TEMPS-A) 
was used to assess affective temperaments on depres-
sive, cyclothymic, hyperthymic, irritable and anx-
ious subscales, requiring ‘yes’ (score 1) or ‘no’ (score 
0) answers (Akiskal et al., 2005). TEMPS-A, which 
contains 110 items (109 in the version for males), 
has been extensively studied, translated into more 
than 25 languages and validated in several of the 
latter. 
The Big Five Inventory (BFI-44) was used to meas-
ure the five big dimensions of personality; extraver-
sion, agreeableness, conscientiousness, neuroticism 
and openness (John and Srivastava, 1999). On the 
44-item questionnaire, each item is answered on a 
5-point scale ranging from 1 (strongly disagree) to 
5 (strongly agree).
The Berkeley Expressivity Questionnaire (BEQ) 
was used to evaluate the subjects' emotional expres-
sivity. The 16-item scale is separated into 3 facets: 
negative expressivity, positive expressivity and im-
pulse strength (Gross and John, 1997). Each item is 
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answered on a 7-point scale ranging from 1 (strongly 
disagree) to 7 (strongly agree). 
The Pain Vigilance and Awareness Questionnaire 
(PVAQ), a 16-item instrument was used to measure 
the subjects' pain vigilance and awareness (Roelofs 
et al., 2003). All items are rated on a scale: 0 (never) 
to 5 (always). 
Measures of blood pressure and arterial stiffness
Measurements were performed in a temperature-
controlled room, between 7.00 and 8.00 a.m. prior 
to blood collection. Patients were required to fast 
overnight and refrain from smoking and drinking 
caffeine-containing beverages before the procedure, 
but to take their usual blood pressure medication 
(only at the follow-up visit). Upon arrival and after a 
5-minute rest, two brachial blood pressure measure-
ments were taken on each arm in the sitting position 
with a validated oscillometric blood pressure device 
(Omron M3). The mean value from the arm with 
the higher value was further used as brachial systolic 
(SBPbrach) and diastolic (DBPbrach) blood pressure 
and heart rate. Brachial pulse pressure (PPbrach) was 
also calculated from these data. The subjects were next 
fitted with an arterial stiffness measurement device 
and were asked to rest in the supine position for ap-
proximately 15 minutes before being measured. Arte-
rial stiffness and central haemodynamic parameters 
were evaluated with the gold-standard tonometric 
method (PulsePen, DiaTecne, Milan, Italy) (Salvi et al., 
2004). This method provides estimates of pulse wave 
velocity (PWV), augmentation index (Aix), central 
systolic blood pressure (SBPcentr), and central pulse 
pressure (PPcentr). In each subject, two sequences of 
arterial stiffness measurements were performed and 
their mean was used for statistical analysis. In PWV 
calculations, 80% of the carotid-femoral distance was 
used, according to the most recent recommendation 
(Van Bortel et al., 2012). The intra- and interobserver 
variability of PWV measurements obtained by the 
PulsePen device in hypertensive patients was 4.6 and 
6.3%, respectively. Since PulsePen calculates pressures 
based on brachial diastolic blood pressure calibration, 
the calculated central diastolic blood pressure is iden-
tical to the brachial diastolic blood pressure assessed 
in the supine position (Salvi et al., 2004). 
Measurement of seBDNF concentration
Peripheral blood samples of patients were collected in 
anticoagulant-free tubes, right after the measurement 
of arterial stiffness. After centrifugation (3600 rpm 
for 6 min) the serum was stored at −20°C. SeBDNF 
was measured using commercially available sand-
wich enzyme-linked immunosorbent assay (R&D 
Systems, Minneapolis MN, USA) according to the 
manufacturer's protocol and serum BDNF level was 
determined in ng/mL.
Statistical analysis
Normality of the parameters was tested with the 
Kolmogorov-Smirnov test. Descriptive character-
istics, laboratory, arterial stiffness, haemodynamic 
parameters and psychometric scores were compared 
between CONT and HT groups using 2-sample Stu-
dent's t-tests or independent samples Mann–Whit-
ney rank-sum test for data failing tests of normality 
at baseline. Laboratory, arterial stiffness, haemody-
namic and psychometric variables were compared 
between baseline and follow-up within the HT group 
using paired Student's–t-tests or dependent samples 
Mann–Whitney rank-sum test for data failing tests 
of normality. We also run a sensitivity analysis on 
participants with already known hypertension under 
our care who received lifestyle education before study 
initiation to minimize study effect related to care 
initiation and education.
Data are expressed as mean ± standard deviation 
or median with interquartile ranges. For psychomet-
ric parameters with non-normal distribution mean 
with interquartile ranges are presented. P<0.05 was 
considered to be significant. SPSS 22.0 for Windows 
was used for all calculations. 
RESULTS 
Altogether 31 patients with hypertension and 22 con-
trols were included in the cross-sectional analysis. 
15 of the 31 hypertensive patients were already in 
hypertension care and were previously educated for 
lifestyle modifications. The other 16 of them were 
educated around study involvement. All 31 hyperten-
sive patients completed the 3-month follow-up and 
were included in the longitudinal analysis. 
The final antihypertensive and vasculoprotective 
medications of the hypertensive group at follow-up 
are shown in table 1. More than 80% of the patients 
received the ACE-inhibitor perindopril and three-
quarter the calcium-channel blocker amlodipine. 
Only 4 patients were on indapamide therapy, 2 of 
them took the ARB losartan. Altogether 12 patients 
required beta-blockers and bisoprolol was the most 
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frequently used. Only one patient received additional 
blood pressure lowering drug (doxazosin). Equally 3 
patients were on statin and acetylsalicylic acid therapy, 
but none of them were initiated parallel with the an-
tihypertensive medication. Most of the patients were 
on a dual combination of antihypertensive agents. 
In the hypertensive group 4 patients (12.9%) were 
treated for gastroesophageal reflux disease, 3 patients 
(9.7%) for hypercholesterinaemia, equally 2 patients 
(6.4%) had gout, bronchial asthma, inflammatory 
bowel disease or non-pharmacologically treated type 
2 diabetes and 1 patient (3.2%) had peripheral artery 
disease. 
Baseline demographic, laboratory, haemodynamic 
and arterial stiffness parameters are shown in table 
2. CONT subjects were younger than HT subjects. 
Their waist circumference, BMI, blood glucose, uric 
acid, total cholesterol and triglyceride levels were 
lower that of hypertensive patients’ at baseline. No 
significant changes in these parameters were found 
after 3 months of antihypertensive treatment. All bra-
chial and central haemodynamic and arterial stiffness 
parameters were impaired in hypertensive compared 
with control subjects and all improved significantly 
with blood pressure medication.
Table 3. demonstrates psychometric measures 
of the groups at baseline and follow-up. Anxiety 
measured by HAM-A, somatization, obsessiveness-
compulsiveness and positive symptom distress index 
measured by SCL-90, overall emotional expressivity 
and negative emotional facet scores of the Berkeley 
Expressivity Questionnaire were significantly different 
between the hypertensive and control groups. After 
3 months of antihypertensive treatment depression 
score measured by BDI improved significantly with 
0.73 points. Many SCL-90 dimensions also improved 
during follow-up, such as somatization, obsessive-
ness-compulsiveness, interpersonal sensitivity, anxi-
ety, psychoticism, the global severity index and the 
positive symptom total.
Our sensitivity analysis on 15 patients already 
under care for hypertension before study initiation 
showed similar point estimates to the main analysis 
although some of the changes did not reach statistical 
significance (results are available on request.)
DISCUSSION
The results of the present study demonstrated, that 
in newly diagnosed hypertensive patients free from 
psychiatric disorders the initiation of currently rec-
ommended antihypertensive medications markedly 
improves blood pressure and arterial stiffness and 
also beneficially effects depression and psychiatric 
symptoms in different directions of psychopathologi-
cal dimensions, besides unchanged seBDNF. 
Angiotensin-converting enzyme (ACE) mediates 
the production of angiotensin II, which, throughout 
its brain receptors besides its important role in blood 
pressure control (Unger et al., 1988) also participates 
in the regulation of mood (Gard et al., 1999). In our 
study, more than 80% of the hypertensive patients 
received the ACE-inhibitor perindopril. In contrast 
to enalapril, perindopril due to its high lipophilicity 
and central nervous system (CNS) permeability, is 
regarded as centrally active agent. It has been found 
to ameliorate cognitive impairment in an animal 
model of vascular dementia (Yamada et al., 2011). 
However, its antidepressant effect has not been stud-
ied so far.
More than 70% of our patients were taking the 
calcium channel blocker amlodipine therapy. Accord-
ing to a previous study in hypertensive patients with 
coronary artery disease, verapamil-based treatment 
improved depressive symptoms during one-year 
follow-up (Ried et al., 2005). Similarly to verapamil 
and perindopril, amlodipine also penetrates into the 
CNS, where it may have beneficial pleiotropic effects, 
such as potentiating the antiepileptic effect of lamo-
trigine, suggested by an animal study (Luszczki et 
al., 2007). Moreover, in spontaneously hypertensive 
rats the concomitant administration of amlodipine 
and atorvastatin improves cognitive dysfunction and 
exerts antioxidant effects in the hippocampus and in 
the rostral ventricular medulla (Kishi and Sunagawa, 
2012). Although animal data are accumulating on 
the neuroprotective role of amlodipine in the CNS, 
no data are currently available regarding its effect 
on psychometric parameters in humans. Therefore 
our data are the first to show the possible beneficial 
psychiatric effect of perindopril and amlodipine, two 
very popular antihypertensive medications.
Another possible pathophysiological mechanism 
that may explain our findings may be the influence of 
the used medications on the hypothalamic-pituitary-
adrenal (HPA) axis, which plays an important role 
in depression and other psychopathological condi-
tions as well as in cardiovascular pathology (Penninx, 
2016). In animal models both the administration of 
the ACE-inhibitor ramipril or different calcium chan-
nel blockers were found to reduce HPA axis activity 
(Raasch et al., 2006; Kumar et al., 2012). 
The possible effect of neurotrophins has never 
been studied in this context yet. Although we re-
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 Table 1.  Antihypertensive and vasculoprotective medications of HT2 group
Regular medications N (total=31)
ACE inhibitor (perindopril) 26 (83.9 %)
Angiotensin-receptor blocker (losartan) 2 (6.5 %)
Calcium channel blocker (amlodipine) 22 (71.0 %)
Beta-blockers 12 (38.7 %)
bisoprolol 7 (22.6 %)
carvedilol 2 (6.5 %)
metoprolol 1 (3.2 %)
nebivolol 2 (6.5 %)
Alfa-adrenergic receptor blocker (doxazosin) 1 (3.2 %)
Diuretic (indapamid) 4 (12.9 %)
Antiplatelet medications 3 (9.7 %)
Statins 3 (9.7 %)
1 type of antihypertensive agent 4 (12.9 %)
2 types  of antihypertensive agents 19 (61.3 %)
3 types of antihypertensive agents 6 (19.4 %)
4 types of antihypertensive agents 2 (6.4 %)
Table 2.  Demographic, laboratory, haemodynamic and arterial stiffness parameters of controls (CONT)  
and hypertensive patients at baseline (HT1) and during therapy (HT2)
CONT HT1 HT2
Subjects [man/woman] 22 (8/14) 31 (22/9) 31 (22/9)
Age [year] 31 (26-41.2) 47 (38-63)* 48 (39-63)
Smoking [n (%)] 4 (18.2%) 10 (32.3%) 10 (32.3%)
Waist circumference [cm] 83 (77-93) 98.5 (91-105)* 97 (94-104.5)
BMI [kg/m2] 22.9 (2.9) 28.6 (5.4)* 28.3 (5.4)
Blood glucose [mmol/l] 4.9 (4.7-5.3) 5.1 (4.8-5.9)* 5.4 (4.9-5.5)
eGFR-EPI [mmol/l] 87.1 (19.9) 88.4 (17.1) 88.0 (17.6)
Uric acid [µmol/l] 299.9 (76,6) 357.9 (79.2)* 381.2 (97.6)
Total cholesterol [mmol/l] 4.8 (0.79) 5.9 (1.04)* 5.6 (1.04)
Triglyceride [mmol/l] 0.8 (0.28) 1.9 (0.83)* 1.9 (1.06)
SBPbrach [Hgmm] 117.1 (10.1) 153.3 (15.9)* 129.5 (10.0)#
DBPbrach [Hgmm] 70 (64-71.2) 91.5 (85.6-99.2)* 80.5 (73.5-85)#
PPbrach [Hgmm] 49.7 (8.2) 57.9 (11.3)* 50.6 (10.2)#
Heart rate [1/min] 68.1 (9.3) 79.7 (12.5)* 74.5 (9.3)#
SBPcentr [Hgmm] 112.4 (8.4) 138.1 (14.2)* 121 (11.5)#
DBPcentr [Hgmm] 65.9 (6.8) 84.4 (8.5)* 74.7 (7.6)#
PPcentr [Hgmm] 46.5 (7.6) 53.8 (12.1)* 46.3 (10.4)#
Augmentation index [%] 1.7 (13.2) 18.3 (16.8)* 10.1 (17.3)#
PWV [m/sec] 6.2 (0.9) 8.2 (1.4)* 7.5 (1.6)#
seBDNF (ng/ml) 22.7 (20.4-26.2) 22.1 (18.2-28.7) 23.9 (17.9-28.4)
Continuous data are presented as mean (± SD) or medians (25-75 percentiles). CONT: control subjects; HT1: hypertensive patients before 
blood pressure medication; HT2: treated hypertensive patients 3 months after initiation of medication. BMI: body mass index; eGFR-EPI: 
glomerular filtration rate assessed by the chronic kidney disease epidemiology collaboration glomerular filtration rate equation; SBPbrach: 
brachial systolic blood pressure; DBPbrach: brachial diastolic blood pressure; PPbrach: brachial pulse pressure; SBPcentr: central systolic 
blood pressure; DBPcentr: central diastolic blood pressure; PPcentr: central pulse pressure; PWV: pulse wave velocity; seBDNF: serum brain-
derived neurotrophic factor. * p<0.05 between CONT-HT1; # p<0.05 between HT1-HT2. 
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Table 3.  Comparison of psychometric scores of hypertensive at baseline and during therapy and control patients
CONT HT1 HT2
BDI 3.8 (0-6) 5.1 (2-8) 4.4 (0-7)#
HAM-A 4.1 (4.1) 6.4 (6.0)* 7.8 (8.0)
SCL-90-R
Somatization 2.7 (1-4) 8.7 (3.7-13.5)* 5 (2-6)#
Obsessiveness-compulsiveness 10.5 (3.9) 14.9 (10-17.2)* 12.1 (8.7-14)#
Interpersonal sensitivity 3.4 (0.2-5) 5.1 (0-7.2) 3.5 (0-6.5)#
Depression 4.8 (2-5.7) 5.8 (0-5.7) 4.2 (0-4.5)#
Anxiety 2.9 (1-4.7) 5.2 (0.7-8.2) 3.5 (0-6.5)#
Hostility 1.6 (0-2.7) 2.2 (0-2) 1.5 (0-2)
Phobic anxiety 0.5 (0-1) 1.6 (0-2) 1.4 (0-2)
Paranoid ideation 1.5 (0-2) 2.9 (0-4.2) 2.6 (0-3.2)
Psychoticism 1.5 (0-2) 3.6 (0-4.2) 1.7 (0-2) #
GSI 0.3 (0.1-0.4) 0.5 (0.1-0.6) 0.4 (0.1-0.5)#
PSDI 1.3 (1.1-1.4) 1.6 (1.1-1.8)* 1.5 (1.1-2)
PST 17.9 (10-26) 23.5 (10-27.2) 19.8 (5.7-32)#
TEMPS-A
Depressive 6.6 (5-8) 6 (4-8) 6.2 (3-8)
Irritable 4.1 (2-5) 4.4 (2-6) 4.6 (2-5)
Anxious 4.6 (2-6) 4.3 (1-7) 4.8 (1-6)
Hyperthymic 11.8 (8-15) 13.8 (11-15) 12.9 (11-14)
Cyclothymic 3.5 (1-7) 4.2 (1-7) 3.9 (1-5)
BFI-44
Extraversion 3.6 (3.1-4) 3.9 (3.5-4.2) 3.7 (3.4-4.2)
Agreeableness 3.8 (3.2-4.2) 3.9 (3.4-4.2) 3.8 (3.6-4.4)
Conscientiousness 3.8 (0.7) 4.1 (0.5) 4.1 (0.5)
Neuroticism 2.5 (2.2-2.7) 2.3 (1.7-2.9) 2.3 (1.9-2.6)
Openness 4.0 (0.8) 4.1 (0.4) 4.0 (0.6)
Berkeley Expressivity Questionnaire
Overall emotional expressivity 75 (71-84) 66.8 (57-75)* 65.7 (60-73)
Negative emotionality facet 26 (5.2) 22 (7.7)* 22.1 (6.9)
Positive emotionality facet 23.4 (4.1) 22.96 (4.2) 21.4 (4.8)
Impulse strength facet 24.7 (7.7) 21.8 (7.2) 22.2 (8.4)
The Pain Vigilance and Awareness Questionnaire
Sum 38.8 (13.3) 45.5 (13.6) 42.8 (14)
Continuous data are presented as mean (± SD) or means (25-75 percentiles). BDI: Beck Depression Inventory; HAM-A: Hamilton Anxiety 
Scale; SCL-90-R: SCL-90 autoquestionnaire; GSI: global severity index; PSDI: positive symptom distress index; PST: positive symptom total. 
TEMPS-A: Temperament Evaluation of Memphis, Pisa, Paris and San Diego Autoquestionnaire; BFI-44: The Big Five Inventory; * p<0.05 
between CONT-HT1; # p<0.05 between HT1-HT2. 
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cently reported, that in treated chronic hyperten-
sion seBDNF is elevated compared with controls and 
chronic hypertension is an independent determinant 
of seBDNF (Nemcsik et al., 2016), but in our study 
seBDNF was not elevated in untreated hypertensive 
patients. Previously perindopril and the combina-
tion of amlodipine and irbesartan were both found 
to modify BDNF beneficially on cellular level (Ali 
et al., 2016; Hasegawa et al., 2016), but contrary to 
expectations, in our study seBDNF was unchanged 
after three months of mostly perindopril and/or 
amlodipine based therapy, although a tendency of 
increase appeared. As in our previous study the aver-
age duration of hypertension was 11 years (Nemcsik 
et al., 2016), it is plausible, that seBDNF elevation is 
not an acute event, but might be a part of a long-term 
compensatory process. Longer follow-up and higher 
number of untreated hypertensive patients involved 
would be required to clarify this question as well as 
the possible impact of particular antihypertensive 
agent groups on seBDNF.
Personality is thought to be relatively stable 
throughout the lifespan, but their quantitative chang-
es considered important research question (Ibanez et 
al., 2016). Temperament is regarded as an inherited 
part of personality and represents the biologically 
stable core of emotional reactivity (Bouchard, 1994); 
although, there is an ongoing discussion regarding 
the influence of age on depressive temperament with 
differences between men and women (Vazquez et al., 
2012). Furthermore, psychoactive medications were 
found to have an effect on personality measures. For 
example, paroxetine was shown to have a specific 
pharmacologic effect on measures of neuroticism and 
extraversion in major depressive disorder independ-
ent from its effect on depression (Tang et al., 2009). 
Based on these findings, it seemed to be reasonable 
to study the potential effect of centrally active cur-
rently recommended antihypertensive medications 
on personality. In the present study no significant 
changes in affective temperaments and in the big 
five dimensions of personality were found after the 
initiation of antihypertensive medications, thus our 
results may indicate that these agents do not influ-
ence measures of these personality constructs.
It is important to note that low levels of blood 
pressure can also be associated with depression, es-
pecially in the elderly (Kim et al., 2010). Moreover, 
according to a study performed in elderly subjects 
between 1991 and 1995, low diastolic blood pressure 
and a decrease of either systolic or diastolic blood 
pressure during a two-year follow-up was associated 
with an increase of depressive symptoms. While only 
25% of patients took any antihypertensive medica-
tions (very likely old-type agents), the results were 
unchanged when patients on antihypertensive medi-
cations were excluded from analysis (Paterniti et al., 
2000). No cut-off blood pressure values were reported 
below which severity of depressive symptoms would 
worsen so far, as in both studies arbitrary blood pres-
sure categories were used based on the study sample 
(the lowest 10 percentile (Kim et al., 2010) or the first 
quartile (Paterniti et al., 2000) of systolic/diastolic 
blood pressure). It is also important to note, that in 
both of these studies the mean age of subjects was 65, 
which is much higher compared with our study. We 
suppose that in younger patients the correction of 
elevated blood pressure with currently recommended 
medications may have beneficial psychological im-
pact while with aging very low blood pressure may 
be associated with psychopathological and somatic 
symptoms. 
Arterial stiffness and central blood pressure were 
also measured in our patients. Carotid-femoral pulse 
wave velocity, the most accepted arterial stiffness 
parameter is recommended for cardiovascular risk 
prediction both in the recent European Hypertension 
Guideline and in an American Heart Association 
scientific statement (Mancia et al., 2013; Townsend 
et al., 2015). As pulse wave velocity changes slowly, 
the remarkable decrease observed in the present study 
reflects the good medication compliance of our par-
ticipants.
There are data available about the possible associa-
tion between arterial stiffness and mood disorders. In 
a population-based cross-sectional study Tiermeier 
et al. found, that patients with increased arterial stiff-
ness were more likely to have depressive symptoms. 
The authors concluded that arterial stiffening may 
partly explain the proposed relationship between vas-
cular factors and depression (Tiemeier et al., 2003). 
Moreover, in middle-aged patients arterial stiffness 
measured by the augmentation index was found to 
be associated with anxiety sensitivity (Seldenrijk et 
al., 2013). Less data is available about the association 
between arterial stiffness and personality traits: low 
hyperthymic affective temperament score was found 
to be associated with an increased level of arterial 
stiffening (Laszlo et al., 2016), while high trait anger 
was found to be associated with arterial stiffness in 
men (Williams et al., 2006). Whether initial arterial 
stiffness or its changes are related to the observed im-
provement of depression and psychiatric symptoms 
and whether they are related to the antihypertensive 
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medications used in our study are questions that 
require further studies with large samples. 
There are several limitations of our study. First, 
the number of patients involved limits the potential 
for multivariable analysis by adjusting for potential 
confounders. As the medication of the patients was 
heterogeneous, the individual contribution of dif-
ferent agents cannot be identified. Additionally, as 
the follow-up period was only 3 months, the stabil-
ity of the observed changes in a longer time period 
still has to be investigated. Moreover, although our 
methodology used standardized questionnaires and 
excluded patients with dementia, a complete exclu-
sion of misinterpretations or mistakes by patients is 
nevertheless impossible. Finally, as our study had a 
non-controlled design, we investigated the effect of at 
least 2 types of interventions: medication effect and 
study effects related to initiation of care (like educa-
tion or discussion with the physician and nurses). 
Although it is impossible to entangle the individual 
effect of these interventions, our sensitivity analysis 
suggest that medication initiation provides a substan-
tial portion of the observed changes in psychometric 
and biological parameters. The major limitation is 
that, due to ethical considerations it is an uncon-
trolled study without a proper control group for the 
follow-up period. 
CONCLUSIONS
In conclusions, currently recommended antihyper-
tensive medications, based on perindopril and/or 
amlodipine might have beneficial impact on depres-
sion and on the intensity of numerous psychiatric 
symptoms. If these effects are confirmed in other 
studies, they may broaden the range of factors con-
sidered when antihypertensive medications are se-
lected.   However, the contribution of identical agents 
or the regular patient care itself and the persistence 
of these effects on longer period of time still needs 
to be clarified.
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Célkitűzés: Az antihipertenzív gyógyszerek pszichológiai hatásával kapcsolatban rendel-
kezésre álló adatok ellentmondásosak. Vizsgálatunk célja a korszerű antihipertenzív ke-
zelés pszichometriai paraméterekre és szérum brain-derived neurotrophic factor (BDNF) 
szintre kifejtett hatásának vizsgálata volt. Módszerek: Gyógyszeres kezelést nem kapó hi-
pertóniás betegekben (HT, n=31) a gyógyszeres kezelés előtt, majd azt követően három 
hónappal, valamint egészséges kontrollokban (CONT, n=22) egyszeri alkalommal vizsgáltunk 
pszichometriai, hemodinamikai, artériás érfalmerevség és vérvételi paramétereket. Az ala-
nyok az alábbi pszichometriai teszteket töltötték ki: Beck Depresszió Kérdőív (BDI), Hamilton 
Szorongás Skála (HAM-A), SCL-90-R Kérdőív (SCL-90), Temperamentum Kérdőív, Big 5 Kérdőív, 
Fájdalom-vigilancia és Tudatosság Kérdőív, Berkeley Kifejezőkészség Kérdőív. Amlodipin és/
vagy perindopril alapú volt az antihipertenzív kezelés. A szérum BDNF szint mérése ELISA-val 
történt. Eredmények: Három hónapos antihipertenzív kezelés hatására a brachiális szisztolés 
vérnyomás (153.3±15.9 Hgmm versus 129.5±10.0 Hgmm) és a pulzushullám terjedési sebesség 
(8.2±1.4 m/s versus 7.5±1.6 m/s) is szignifikánsan csökkent. Ezzel párhuzamosan szignifikáns 
javulást találtunk a BDI pontszámban (0,73 pont) és számos SCL-90 alskálában. A szérum 
BDNF-szint nem különbözött a CONT és a HT csoportok között, és nem változott a gyógyszeres 
kezelés hatására. Következtetések: Eredményeink arra utalnak, hogy gyógyszeres kezelésben 
még nem részesülő hipertóniás betegekben a jelenleg javasolt antihipertenzív hatóanyagok 
bevezetése egyaránt jótékony hatással lehet a pszichés státusra és az életminőségre.
Kulcsszavak: antihipertenzív gyógyszerek, depresszió, pszichiátriai tünetek, affektív tempe-
ramentumok, brain-derived neurotophic factor
A jelenlegi ajánlások szerinti antihipertenzív terápia hatása  
a depresszióra és egyéb pszichometriai paraméterekre:  
előzetes eredmények
